 | • レポートコード：MR2211MG12537 • 出版社/出版日：Market Monitor Global / 2022年11月 • レポート形態：英文、PDF、73ページ • 納品方法：Eメール（納期：2-3日） • 産業分類：製薬・ヘルスケア |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥625,300 (USD4,225) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料は次の情報を含め、循環器疾患治療薬のグローバル市場規模と予測を記載しています。・循環器疾患治療薬のグローバル市場：売上、2017年-2022年、2023年-2028年 ・循環器疾患治療薬のグローバル市場：販売量、2017年-2022年、2023年-2028年 ・世界のトップ5企業、2021年 循環器疾患治療薬のグローバル市場規模は2021年に000Mドルと評価され、予測期間中に000％のCAGRで2028年までに000Mドルに達すると予測されています。米国市場は2021年に000Mドルと推定されており、中国は2028年までに000Mドルに達すると予測されています。「降圧薬」セグメントは今後6年間、000%のCAGRで2028年までに000Mドルに成長すると予測されています。 循環器疾患治療薬のグローバル主要企業は、Crestor、 Zetia、 Vytorin、 Letairis、 Tracleer、 Bystolic、 Opsumit、 Ranexa、 Azilva、 Remodulinなどです。2021年にトップ5企業がグローバル売上シェアの約000%を占めています。 マーケットモニターグローバル（MMG）社は、循環器疾患治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の循環器疾患治療薬市場：タイプ別、2017年-2022年、2023年-2028年 世界の循環器疾患治療薬市場：タイプ別市場シェア、2021年 ・降圧薬、抗狭心症薬、抗凝固薬、抗脂質血症薬、抗心不全薬、抗不整脈薬 世界の循環器疾患治療薬市場：用途別、2017年-2022年、2023年-2028年 世界の循環器疾患治療薬市場：用途別市場シェア、2021年 ・病院、医学研究所、診療所、その他 世界の循環器疾患治療薬市場：地域・国別、2017年-2022年、2023年-2028年 世界の循環器疾患治療薬市場：地域別市場シェア、2021年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における循環器疾患治療薬のグローバル売上、2017年-2022年 ・主要企業における循環器疾患治療薬のグローバル売上シェア、2021年 ・主要企業における循環器疾患治療薬のグローバル販売量、2017年-2022年 ・主要企業における循環器疾患治療薬のグローバル販売量シェア、2021年 さらに、当レポートは主要企業のプロファイルを提示します。 Crestor、 Zetia、 Vytorin、 Letairis、 Tracleer、 Bystolic、 Opsumit、 Ranexa、 Azilva、 Remodulin ************************************************************* ・調査・分析レポートの概要 循環器疾患治療薬市場の定義 市場セグメント 世界の循環器疾患治療薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の循環器疾患治療薬市場規模 世界の循環器疾患治療薬市場規模：2021年 VS 2028年 世界の循環器疾患治療薬市場規模と予測 2017年-2028年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの循環器疾患治療薬の売上 グローバルトップ3およびトップ5企業、2021年売上ベース グローバル企業の循環器疾患治療薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：降圧薬、抗狭心症薬、抗凝固薬、抗脂質血症薬、抗心不全薬、抗不整脈薬 循環器疾患治療薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、医学研究所、診療所、その他 循環器疾患治療薬の用途別グローバル売上・予測 ・地域別市場分析 地域別循環器疾患治療薬市場規模 2021年と2028年 地域別循環器疾患治療薬売上・予測 北米市場 - アメリカの循環器疾患治療薬市場規模2017年-2028年 - カナダの循環器疾患治療薬市場規模2017年-2028年 - メキシコの循環器疾患治療薬市場規模2017年-2028年 ヨーロッパ市場 - ドイツの循環器疾患治療薬市場規模2017年-2028年 - フランスの循環器疾患治療薬市場規模2017年-2028年 - イギリスの循環器疾患治療薬市場規模2017年-2028年 - イタリアの循環器疾患治療薬市場規模2017年-2028年 - ロシアの循環器疾患治療薬市場規模2017年-2028年 アジア市場 - 中国の循環器疾患治療薬市場規模2017年-2028年 - 日本の循環器疾患治療薬市場規模2017年-2028年 - 韓国の循環器疾患治療薬市場規模2017年-2028年 - 東南アジアの循環器疾患治療薬市場規模2017年-2028年 - インドの循環器疾患治療薬市場規模2017年-2028年 南米市場 - ブラジルの循環器疾患治療薬市場規模2017年-2028年 - アルゼンチンの循環器疾患治療薬市場規模2017年-2028年 中東・アフリカ市場 - トルコの循環器疾患治療薬市場規模2017年-2028年 - イスラエルの循環器疾患治療薬市場規模2017年-2028年 - サウジアラビアの循環器疾患治療薬市場規模2017年-2028年 - UAEの循環器疾患治療薬市場規模2017年-2028年 ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Crestor、 Zetia、 Vytorin、 Letairis、 Tracleer、 Bystolic、 Opsumit、 Ranexa、 Azilva、 Remodulin ... |
This report contains market size and forecasts of Cardiovascular Disease Nursing Drugs in global, including the following market information:
Global Cardiovascular Disease Nursing Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Cardiovascular Disease Nursing Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Cardiovascular Disease Nursing Drugs companies in 2021 (%)
The global Cardiovascular Disease Nursing Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Antihypertensive Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cardiovascular Disease Nursing Drugs include Crestor, Zetia, Vytorin, Letairis, Tracleer, Bystolic, Opsumit, Ranexa and Azilva and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cardiovascular Disease Nursing Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cardiovascular Disease Nursing Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Cardiovascular Disease Nursing Drugs Market Segment Percentages, by Type, 2021 (%)
Antihypertensive Drugs
Antianginal Drugs
Anticoagulants
Antilipidemic Drugs
Anti-heart Failure Drugs
Antiarrhythmic Drugs
Global Cardiovascular Disease Nursing Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Cardiovascular Disease Nursing Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Institute of Medicine
Clinic
Others
Global Cardiovascular Disease Nursing Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Cardiovascular Disease Nursing Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cardiovascular Disease Nursing Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Cardiovascular Disease Nursing Drugs revenues share in global market, 2021 (%)
Key companies Cardiovascular Disease Nursing Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Cardiovascular Disease Nursing Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Crestor
Zetia
Vytorin
Letairis
Tracleer
Bystolic
Opsumit
Ranexa
Azilva
Remodulin
1 Introduction to Research & Analysis Reports
1.1 Cardiovascular Disease Nursing Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cardiovascular Disease Nursing Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cardiovascular Disease Nursing Drugs Overall Market Size
2.1 Global Cardiovascular Disease Nursing Drugs Market Size: 2021 VS 2028
2.2 Global Cardiovascular Disease Nursing Drugs Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Cardiovascular Disease Nursing Drugs Sales: 2017-2028
3 Company Landscape
3.1 Top Cardiovascular Disease Nursing Drugs Players in Global Market
3.2 Top Global Cardiovascular Disease Nursing Drugs Companies Ranked by Revenue
3.3 Global Cardiovascular Disease Nursing Drugs Revenue by Companies
3.4 Global Cardiovascular Disease Nursing Drugs Sales by Companies
3.5 Global Cardiovascular Disease Nursing Drugs Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Cardiovascular Disease Nursing Drugs Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Cardiovascular Disease Nursing Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cardiovascular Disease Nursing Drugs Players in Global Market
3.8.1 List of Global Tier 1 Cardiovascular Disease Nursing Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Cardiovascular Disease Nursing Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Cardiovascular Disease Nursing Drugs Market Size Markets, 2021 & 2028
4.1.2 Antihypertensive Drugs
4.1.3 Antianginal Drugs
4.1.4 Anticoagulants
4.1.5 Antilipidemic Drugs
4.1.6 Anti-heart Failure Drugs
4.1.7 Antiarrhythmic Drugs
4.2 By Type – Global Cardiovascular Disease Nursing Drugs Revenue & Forecasts
4.2.1 By Type – Global Cardiovascular Disease Nursing Drugs Revenue, 2017-2022
4.2.2 By Type – Global Cardiovascular Disease Nursing Drugs Revenue, 2023-2028
4.2.3 By Type – Global Cardiovascular Disease Nursing Drugs Revenue Market Share, 2017-2028
4.3 By Type – Global Cardiovascular Disease Nursing Drugs Sales & Forecasts
4.3.1 By Type – Global Cardiovascular Disease Nursing Drugs Sales, 2017-2022
4.3.2 By Type – Global Cardiovascular Disease Nursing Drugs Sales, 2023-2028
4.3.3 By Type – Global Cardiovascular Disease Nursing Drugs Sales Market Share, 2017-2028
4.4 By Type – Global Cardiovascular Disease Nursing Drugs Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application – Global Cardiovascular Disease Nursing Drugs Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Institute of Medicine
5.1.4 Clinic
5.1.5 Others
5.2 By Application – Global Cardiovascular Disease Nursing Drugs Revenue & Forecasts
5.2.1 By Application – Global Cardiovascular Disease Nursing Drugs Revenue, 2017-2022
5.2.2 By Application – Global Cardiovascular Disease Nursing Drugs Revenue, 2023-2028
5.2.3 By Application – Global Cardiovascular Disease Nursing Drugs Revenue Market Share, 2017-2028
5.3 By Application – Global Cardiovascular Disease Nursing Drugs Sales & Forecasts
5.3.1 By Application – Global Cardiovascular Disease Nursing Drugs Sales, 2017-2022
5.3.2 By Application – Global Cardiovascular Disease Nursing Drugs Sales, 2023-2028
5.3.3 By Application – Global Cardiovascular Disease Nursing Drugs Sales Market Share, 2017-2028
5.4 By Application – Global Cardiovascular Disease Nursing Drugs Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region – Global Cardiovascular Disease Nursing Drugs Market Size, 2021 & 2028
6.2 By Region – Global Cardiovascular Disease Nursing Drugs Revenue & Forecasts
6.2.1 By Region – Global Cardiovascular Disease Nursing Drugs Revenue, 2017-2022
6.2.2 By Region – Global Cardiovascular Disease Nursing Drugs Revenue, 2023-2028
6.2.3 By Region – Global Cardiovascular Disease Nursing Drugs Revenue Market Share, 2017-2028
6.3 By Region – Global Cardiovascular Disease Nursing Drugs Sales & Forecasts
6.3.1 By Region – Global Cardiovascular Disease Nursing Drugs Sales, 2017-2022
6.3.2 By Region – Global Cardiovascular Disease Nursing Drugs Sales, 2023-2028
6.3.3 By Region – Global Cardiovascular Disease Nursing Drugs Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country – North America Cardiovascular Disease Nursing Drugs Revenue, 2017-2028
6.4.2 By Country – North America Cardiovascular Disease Nursing Drugs Sales, 2017-2028
6.4.3 US Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.4.4 Canada Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.4.5 Mexico Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.5 Europe
6.5.1 By Country – Europe Cardiovascular Disease Nursing Drugs Revenue, 2017-2028
6.5.2 By Country – Europe Cardiovascular Disease Nursing Drugs Sales, 2017-2028
6.5.3 Germany Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.5.4 France Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.5.5 U.K. Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.5.6 Italy Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.5.7 Russia Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.5.8 Nordic Countries Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.5.9 Benelux Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.6 Asia
6.6.1 By Region – Asia Cardiovascular Disease Nursing Drugs Revenue, 2017-2028
6.6.2 By Region – Asia Cardiovascular Disease Nursing Drugs Sales, 2017-2028
6.6.3 China Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.6.4 Japan Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.6.5 South Korea Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.6.6 Southeast Asia Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.6.7 India Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.7 South America
6.7.1 By Country – South America Cardiovascular Disease Nursing Drugs Revenue, 2017-2028
6.7.2 By Country – South America Cardiovascular Disease Nursing Drugs Sales, 2017-2028
6.7.3 Brazil Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.7.4 Argentina Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Cardiovascular Disease Nursing Drugs Revenue, 2017-2028
6.8.2 By Country – Middle East & Africa Cardiovascular Disease Nursing Drugs Sales, 2017-2028
6.8.3 Turkey Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.8.4 Israel Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.8.5 Saudi Arabia Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
6.8.6 UAE Cardiovascular Disease Nursing Drugs Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Crestor
7.1.1 Crestor Corporate Summary
7.1.2 Crestor Business Overview
7.1.3 Crestor Cardiovascular Disease Nursing Drugs Major Product Offerings
7.1.4 Crestor Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.1.5 Crestor Key News
7.2 Zetia
7.2.1 Zetia Corporate Summary
7.2.2 Zetia Business Overview
7.2.3 Zetia Cardiovascular Disease Nursing Drugs Major Product Offerings
7.2.4 Zetia Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.2.5 Zetia Key News
7.3 Vytorin
7.3.1 Vytorin Corporate Summary
7.3.2 Vytorin Business Overview
7.3.3 Vytorin Cardiovascular Disease Nursing Drugs Major Product Offerings
7.3.4 Vytorin Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.3.5 Vytorin Key News
7.4 Letairis
7.4.1 Letairis Corporate Summary
7.4.2 Letairis Business Overview
7.4.3 Letairis Cardiovascular Disease Nursing Drugs Major Product Offerings
7.4.4 Letairis Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.4.5 Letairis Key News
7.5 Tracleer
7.5.1 Tracleer Corporate Summary
7.5.2 Tracleer Business Overview
7.5.3 Tracleer Cardiovascular Disease Nursing Drugs Major Product Offerings
7.5.4 Tracleer Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.5.5 Tracleer Key News
7.6 Bystolic
7.6.1 Bystolic Corporate Summary
7.6.2 Bystolic Business Overview
7.6.3 Bystolic Cardiovascular Disease Nursing Drugs Major Product Offerings
7.6.4 Bystolic Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.6.5 Bystolic Key News
7.7 Opsumit
7.7.1 Opsumit Corporate Summary
7.7.2 Opsumit Business Overview
7.7.3 Opsumit Cardiovascular Disease Nursing Drugs Major Product Offerings
7.7.4 Opsumit Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.7.5 Opsumit Key News
7.8 Ranexa
7.8.1 Ranexa Corporate Summary
7.8.2 Ranexa Business Overview
7.8.3 Ranexa Cardiovascular Disease Nursing Drugs Major Product Offerings
7.8.4 Ranexa Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.8.5 Ranexa Key News
7.9 Azilva
7.9.1 Azilva Corporate Summary
7.9.2 Azilva Business Overview
7.9.3 Azilva Cardiovascular Disease Nursing Drugs Major Product Offerings
7.9.4 Azilva Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.9.5 Azilva Key News
7.10 Remodulin
7.10.1 Remodulin Corporate Summary
7.10.2 Remodulin Business Overview
7.10.3 Remodulin Cardiovascular Disease Nursing Drugs Major Product Offerings
7.10.4 Remodulin Cardiovascular Disease Nursing Drugs Sales and Revenue in Global (2017-2022)
7.10.5 Remodulin Key News
8 Global Cardiovascular Disease Nursing Drugs Production Capacity, Analysis
8.1 Global Cardiovascular Disease Nursing Drugs Production Capacity, 2017-2028
8.2 Cardiovascular Disease Nursing Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Cardiovascular Disease Nursing Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cardiovascular Disease Nursing Drugs Supply Chain Analysis
10.1 Cardiovascular Disease Nursing Drugs Industry Value Chain
10.2 Cardiovascular Disease Nursing Drugs Upstream Market
10.3 Cardiovascular Disease Nursing Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cardiovascular Disease Nursing Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer